Ketamine Versus Electroconvulsive Therapy for Nonpsychotic Treatment-Resistant Depression: A Cost-Effectiveness Analysis
Electroconvulsive therapy (ECT) is a highly effective intervention for treatment-resistant depression; however, its use has been limited partly because of concerns about cognitive side effects. Evidence for the sustained (>1 month) efficacy of ketamine versus ECT for treatment-resistant depression has only recently been demonstrated. This study aimed to examine the cost-effectiveness—that is, the costs and benefits measured as quality-adjusted life-years (QALYs)—of racemic ketamine versus that of ECT for treatment-resistant depression.
Authors
- Daniel M. Blumberger (ORCID: https://orcid.org/0000-0002-8422-5818)
- Jeffrey S. Hoch (ORCID: https://orcid.org/0000-0002-4880-4281)
- Michael Lebenbaum (ORCID: https://orcid.org/0000-0002-6319-3466)
- Benoit H. Mulsant (ORCID: https://orcid.org/0000-0002-0303-6450)
- Sagar V. Parikh (ORCID: https://orcid.org/0000-0003-4817-3042)
- Paul Kurdyak
- Manish Jha
- Amit Anand
- Venkat Bhat
- Jason Fletcher
Institutions
- Wisconsin Department of Health Services (US)
- St. Michael's Hospital (CA)
- Centre for Addiction and Mental Health (CA)
- University of Wisconsin–Madison (US)
- University of Toronto (CA)
- University of Michigan (US)
- Southwestern Medical Center (US)
- Department of Public Health (US)
- Mass General Brigham (US)
- University of California, Davis (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Psychiatric Services
- Published
- 2026-10-22
- DOI
- https://doi.org/10.1176/appi.ps.20240407
- Primary Topic
- Electroconvulsive Therapy Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00